These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

233 related articles for article (PubMed ID: 21560181)

  • 61. Rescue of NanoLuc luciferase-expressing Senecavirus A with oncolytic activity.
    Liu F; Wang Q; Huang Y; Wang N; Shan H
    Virus Res; 2021 Jan; 292():198232. PubMed ID: 33207264
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Clinical development of oncolytic viruses in China.
    Liang M
    Curr Pharm Biotechnol; 2012 Jul; 13(9):1852-7. PubMed ID: 21740357
    [TBL] [Abstract][Full Text] [Related]  

  • 63. A Roadmap for the Success of Oncolytic Parvovirus-Based Anticancer Therapies.
    Hartley A; Kavishwar G; Salvato I; Marchini A
    Annu Rev Virol; 2020 Sep; 7(1):537-557. PubMed ID: 32600158
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Oncolytic viruses: what's next?
    Bell JC
    Curr Cancer Drug Targets; 2007 Mar; 7(2):127-31. PubMed ID: 17346103
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Viruses: tools for tumor target discovery, and agents for oncolytic therapies - an introduction.
    O'Shea CC
    Oncogene; 2005 Nov; 24(52):7636-9. PubMed ID: 16299525
    [No Abstract]   [Full Text] [Related]  

  • 66. JX-594, a targeted oncolytic poxvirus for the treatment of cancer.
    Merrick AE; Ilett EJ; Melcher AA
    Curr Opin Investig Drugs; 2009 Dec; 10(12):1372-82. PubMed ID: 19943208
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Exploiting diversity: genetic approaches to creating highly potent and efficacious oncolytic viruses.
    Bauzon M; Hermiston TW
    Curr Opin Mol Ther; 2008 Aug; 10(4):350-5. PubMed ID: 18683099
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Canine Adipose-Derived Mesenchymal Stem Cells (cAdMSCs) as a "Trojan Horse" in Vaccinia Virus Mediated Oncolytic Therapy against Canine Soft Tissue Sarcomas.
    Petrov I; Gentschev I; Vyalkova A; Elashry MI; Klymiuk MC; Arnhold S; Szalay AA
    Viruses; 2020 Jul; 12(7):. PubMed ID: 32664672
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Oncolytic Viruses and Their Potential as a Therapeutic Opportunity in Osteosarcoma.
    Wedekind MF; Cripe TP
    Adv Exp Med Biol; 2020; 1258():77-89. PubMed ID: 32767235
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Turning killer into cure -- the story of oncolytic herpes simplex viruses.
    Zhang SX
    Discov Med; 2015 Nov; 20(111):303-9. PubMed ID: 26645902
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Unleashing the therapeutic potential of oncolytic viruses.
    Bommareddy PK; Kaufman HL
    J Clin Invest; 2018 Apr; 128(4):1258-1260. PubMed ID: 29504947
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Naturally oncolytic viruses.
    Roberts MS; Lorence RM; Groene WS; Bamat MK
    Curr Opin Mol Ther; 2006 Aug; 8(4):314-21. PubMed ID: 16955694
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Recombinant viruses with other anti-cancer therapeutics: a step towards advancement of oncolytic virotherapy.
    Lal G; Rajala MS
    Cancer Gene Ther; 2018 Oct; 25(9-10):216-226. PubMed ID: 29735993
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Development of a selective biopharmaceutical from Herpes simplex virus type 1 glycoproteins E and I for blocking antibody mediated neutralization of oncolytic viruses.
    Bucurescu S
    Acta Pharm; 2010 Dec; 60(4):407-13. PubMed ID: 21169133
    [TBL] [Abstract][Full Text] [Related]  

  • 75. A mathematical model of oncolytic virotherapy with time delay.
    Wang ZZ; Guo ZM; Smith H
    Math Biosci Eng; 2019 Mar; 16(4):1836-1860. PubMed ID: 31137188
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Crosstalk between oncolytic viruses and autophagy in cancer therapy.
    Jin KT; Tao XH; Fan YB; Wang SB
    Biomed Pharmacother; 2021 Feb; 134():110932. PubMed ID: 33370632
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Developing oncolytic viruses for clinical use: A consortium approach.
    Kemp V; Lamfers MLM; van der Pluijm G; van den Hoogen BG; Hoeben RC
    Cytokine Growth Factor Rev; 2020 Dec; 56():133-140. PubMed ID: 32553482
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Rethinking herpes simplex virus: the way to oncolytic agents.
    Campadelli-Fiume G; De Giovanni C; Gatta V; Nanni P; Lollini PL; Menotti L
    Rev Med Virol; 2011 Jul; 21(4):213-26. PubMed ID: 21626603
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Pro-oncogenic cell signaling machinery as a target for oncolytic viruses.
    Borrego-Diaz E; Mathew R; Hawkinson D; Esfandyari T; Liu Z; Lee PW; Farassati F
    Curr Pharm Biotechnol; 2012 Jul; 13(9):1742-9. PubMed ID: 21740363
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Progress of oncolytic viruses in sarcomas.
    Lettieri CK; Hingorani P; Kolb EA
    Expert Rev Anticancer Ther; 2012 Feb; 12(2):229-42. PubMed ID: 22316371
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.